Results 321 to 330 of about 140,297 (347)
Some of the next articles are maybe not open access.
Antibody drug conjugates: the future of chemotherapy?
Current Opinion in Oncology, 2016Purpose of review The current review describes the rationale and current clinical development of antibody drug conjugates (ADCs), along with their perspectives for the future. Recent findings Trastuzumab emtansine was the first ADC approved by the U.S.
Borcoman, Edith, Le Tourneau, Christophe
openaire +4 more sources
Payloads of Antibody: Drug Conjugates
2015The payload of antibody–drug conjugates (ADCs) is the warhead of ADCs that kills the tumor cells. Three classes of highly potent toxins including maytansinoids, auristatins, and calicheamicins are currently being employed or pursued in the clinic as the payloads of ADCs.
openaire +2 more sources
ADME of Antibody Drug Conjugates
2019Antibody drug conjugates (ADCs) represent a relatively new therapeutic modality, mainly focused towards the treatment of cancer. ADCs are monoclonal antibodies with covalently bound cytotoxic drugs. ADC tissue distribution is driven by the targeting properties of the antibody and as such its distribution is led through the lymphatic system resulting in
Jiajie Yu +2 more
openaire +2 more sources
Building Antibody-Drug Conjugates
Chemical & Engineering News Archive, 2014They’re here. Antibody-drug conjugates, target-seeking molecular missiles with lethal payloads, have arrived.
openaire +2 more sources
Resistance to Antibody-Drug Conjugate
2019Immune therapies have shown significant efficacy in the treatment of pediatric lymphomas. Monoclonal antibodies, whether naked or conjugated have emerged as an attractive option for targeted therapy while minimizing toxicities. Monoclonal antibodies conjugated to small molecule drugs were developed as a way to combine highly potent agents with tumor ...
Jessica Hochberg, Sarah Alexander
openaire +2 more sources
Rethinking Antibody-Drug Conjugates
Chemical & Engineering News Archive, 2012Not long after Daniel Junius joined ImmunoGen as its head of finance, he came across his employer’s name in a lengthy feature in the New York Times. The 2007 story was about “zombie biotechs,” and it called out ImmunoGen as one of a handful of companies that for decades lurched along, pursuing a single technology without ever getting a product onto the
openaire +2 more sources
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Signal Transduction and Targeted Therapy, 2022Sifei Han, Chen Shi, Yu Zhang
exaly
Multifunctional biocatalyst for conjugate reduction and reductive amination
Nature, 2022Thomas W Thorpe +2 more
exaly